The cost offsets and cost–effectiveness associated with pegylated drugs: a review of the literature

The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK

(2012) Zhimei Liu et al.   Applied Health Economics and Health Policy

Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim

(2010) Panagiotis Samaras et al.   ANNALS OF HEMATOLOGY

Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil

(2010) Marcelo Cunio Machado Fonseca et al.   Brazilian Journal of Infectious Diseases

Pegfilgrastim vs. Filgrastim zur Primärprophylaxe der febrilen Neutropenie bei Brustkrebspatientinnen nach Chemotherapie

(2010) J Sehouli et al.   DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT

Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial

(2010) F. Carrera et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-Induced neutropenia

(2009) Mark L. Heaney et al.   CANCER

Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the united states

(2009) Gary H. Lyman et al.   CLINICAL THERAPEUTICS

Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States

(2009) Gary Lyman et al.   CURRENT MEDICAL RESEARCH AND OPINION

PEG-modified biopharmaceuticals

(2009) Pascal Bailon et al.   Expert Opinion on Drug Delivery

Emerging PEGylated drugs

(2009) Jung Seok Kang et al.   EXPERT OPINION ON EMERGING DRUGS

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report—Part II

(2009) Louis P. Garrison et al.   VALUE IN HEALTH

Economic Analysis of Prophylactic Pegfilgrastim in Adult Cancer Patients Receiving Chemotherapy

(2007) Adi Eldar-Lissai et al.   VALUE IN HEALTH